COVID-19 Therapeutics Accelerator

What COVID-19 Therapeutics Accelerator does

The COVID-19 Therapeutics Accelerator (CTA) is a philanthropic collaboration launched in March 2020 by the Bill & Melinda Gates Foundation, Wellcome Trust, and Mastercard Impact Fund to research, develop, and deliver effective COVID-19 treatments quickly and accessibly. It operates as a coordinated funding mechanism rather than a commercial entity, channeling grants to investigators and institutions across the therapeutic development lifecycle from drug screening and discovery through clinical trials, manufacturing scale-up, and real-world evidence generation. As of October 26, 2020, CTA had awarded over $98.6 million in grants split across Discovery ($21.6M), Clinical ($50.4M), Manufacturing ($2.8M), Real World Evidence and Data Platforms ($9.4M), and Diagnostics ($14.5M).

CTA's core technology stack consists of adaptive clinical trial platforms that use modern statistical methods to test multiple drugs in parallel, real-world evidence and data-sharing platforms for global collaborators, and compound library screening infrastructure that leverages proprietary molecular libraries shared by pharmaceutical partners. The organization has funded named trials including WHIP (3,000 health workers), COPCOV (40,000 health workers), CROWN CORONATION (up to 30,000 health workers), COLCORONA (6,000 outpatients), and the AGILE and AVID-CC adaptive trials, spanning geographies across North America, South America, Europe, Africa, and Asia.

CTA's business model is a philanthropic grant-making model with no commercial revenue stream. Funding is sourced from three founding donors plus at least 15 additional donors committing $1 million or more, including major foundations, government donors (UK FCDO, Luxembourg, Norway, Switzerland), and individuals. The Gates Foundation hosts and manages the website and Proposal Portal, while governance rests with the Core Donors. The go-to-market motion is non-commercial: CTA reaches investigators through a Proposal Portal for therapeutic and diagnostic concepts, coordinates with WHO through the ACT-A Therapeutics Partnership, and aligns with manufacturers to ensure dedicated capacity for low- and middle-income country supply. The targeted outcome is 245 million treatment courses delivered to LMICs within approximately one year of promising registered drugs being identified.

Name

COVID-19 Therapeutics Accelerator

Legal name

COVID-19 Therapeutics Accelerator

Website

https://therapeuticsaccelerator.org

Company type

Private

Founded year

2020

Operating status

Operating

Short description

COVID-19 Therapeutics Accelerator is a philanthropic collaboration launched in March 2020 by the Gates Foundation, Wellcome Trust, and Mastercard. It funds and coordinates end-to-end COVID-19 therapeutic development—from drug screening through clinical trials and manufacturing—targeting equitable access in low- and middle-income countries.

Ownership category

akta.pro rank

Product category

Public Health Grant Funding

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Pharmaceutical research grants
• Clinical trial funding
• Therapeutic development
• Global health philanthropy
• Pandemic drug pipeline

GTM type

B2B

Offering type

Services

Cost components

Others, Personnel, Operations

Revenue model

1. Philanthropic Grants and Donations: The CTA is funded through contributions from founding donors (Gates Foundation, Wellcome Trust, Mastercard) and additional contributing donors. The organization awards grants to researchers and institutions working on COVID-19 therapeutics. This is a philanthropic model, not a commercial revenue-generating entity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

The COVID-19 Therapeutics Accelerator is a philanthropic collaboration that provides grant funding and coordination for COVID-19 therapeutic research, development, and scale-up. It supports an end-to-end pipeline from drug discovery and preclinical evaluation through adaptive clinical trials, manufacturing scale-up, and equitable global access, with emphasis on prophylaxis and treatment of mild-to-moderate COVID-19.

Product overview

The COVID-19 Therapeutics Accelerator is a unified funding and coordination initiative (not a traditional software product) that supports end-to-end COVID-19 therapeutic development from pipeline through manufacturing. The initiative centers on grant funding for clinical trials across prophylaxis and mild disease treatment use cases, including named trials such as WHIP, COPCOV, CROWN CORONATION, COLCORONA, AGILE, and AVID-CC. An internal Proposal Portal managed by the Gates Foundation allows submission and review of therapeutic research proposals. The portfolio covers small molecule drugs, monoclonal antibodies, and polyclonal antibodies/plasma therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• COVID-19 Therapeutics Accelerator (CTA) Initiative A philanthropic funding and coordination initiative that supports end-to-end research, development, and scale-up of COVID-19 treatments from drug pipeline through manufacturing, focusing on prophylaxis and early disease treatment for equitable global access.
• Clinical Trial Investments

Quantifiable outcome

• 245 million courses of treatment targeted for delivery in low- and middle-income countries
• +1 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• ACT-A (Access to COVID-19 Tools Accelerator)coreStrategic or Co-development PartnerCTA is represented in the Therapeutics Partnership of ACT-A, coordinating with WHO, governments, private sector, and global health organizations to accelerate development, production, and equitable access to COVID-19 treatments.
• World Health Organization (WHO)coreStrategic or Co-development PartnerCTA coordinates with the Therapeutics Partnership of ACT-A working with WHO and global regulators to help accelerate development of safe, effective and accessible drugs.
• Gates Medical Research InstitutesupportingStrategic or Co-development PartnerA Gates Foundation subsidiary (non-profit biotech) conducting clinical trials for COVID-19 therapeutics. Gates Philanthropy Partners is contributing to an investment in the Institute to conduct these trials.
• UnitaidsupportingStrategic or Co-development PartnerCollaborates with CTA within the Therapeutics Partnership to support development of procurement and delivery frameworks for effective treatments to reach people in low- and middle-income countries.
• Proprietary Compound Libraries (Various Companies)supportingTechnology or IntegrationMultiple companies agreed to share proprietary libraries of molecular compounds with existing safety and activity data to quickly screen them for potential COVID-19 use.
• Research Networks and Academic InstitutionssupportingStrategic or Co-development PartnerExisting collaborative networks of researchers and academic institutions transitioning work to support rapid assessments of therapeutics identified by the CTA.
• Pharmaceutical ManufacturerssupportingStrategic or Co-development PartnerWorking with manufacturers of active pharmaceutical ingredients and finished therapeutic products to ensure dedicated capacity to manufacture and supply promising therapeutic candidates for low- and middle-income countries.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Coalition for Epidemic Preparedness Innovations (CEPI): CEPI is a direct peer — a global partnership between public, private, philanthropic, and civil society organizations that funds and coordinates vaccine and therapeutic R&D for epidemic and pandemic threats. Like CTA, it pools philanthropic and government capital to accelerate development and ensure equitable access, and the two initiatives coordinate within the ACT-A framework.
• Biomedical Advanced Research and Development Authority (BARDA): BARDA is a US government counterpart that funds advanced R&D of medical countermeasures, including therapeutics, vaccines, and diagnostics for pandemic threats. It uses a similar at-risk funding model to accelerate development and coordinates with CTA within ACT-A, making it a direct functional peer in pandemic therapeutics funding.
• Drugs for Neglected Diseases initiative (DNDi): DNDi is a nonprofit R&D organization that develops treatments for neglected diseases using a not-for-profit, collaborative model. It shares CTA's funding/coordination model and equitable access focus, though it concentrates on diseases of poverty rather than pandemic pathogens.
• Medicines for Malaria Ventures (MMV): MMV is a product development partnership that funds and coordinates R&D for antimalarial drugs. CTA explicitly partners with MMV (e.g., ReACT trial for mild COVID-19 in South Africa), and both share a public-interest, donor-funded, partnership-driven model for therapeutic development in LMICs.

Broad incumbents

• Global Fund to Fight AIDS, Tuberculosis and Malaria: The Global Fund is a major international financing mechanism for HIV, TB, and malaria programs. Like CTA, it pools donor capital to address global health threats and is a peer in the philanthropic/government R&D and access funding ecosystem.
• National Institutes of Health (NIH) / NIAID: NIH/NIAID is the largest public funder of biomedical research globally and coordinates COVID-19 therapeutic trials in the US. It is a broader peer to CTA in funding and running large-scale COVID-19 therapeutic development programs.
• Unitaid: Unitaid is a global health financing mechanism that funds and accelerates development and equitable access to health products for HIV, TB, malaria, and now COVID-19. It is a strategic partner of CTA within ACT-A and a broader incumbent in the global-health R&D funding space.
• Gavi, the Vaccine Alliance: Gavi is a public-private global health partnership that funds vaccine procurement and delivery for LMICs. It is one of the co-leads of the ACT-A vaccines pillar and a broader peer to CTA in global-health funding and equitable access architecture.

Emerging players

• Foundation for Innovative New Diagnostics (FIND): FIND is a global nonprofit that drives diagnostic innovation and access, particularly for LMICs. It is a direct ACT-A partner alongside CTA for the diagnostics pillar, making it a functional peer in pandemic-related R&D funding and coordination.
• Wellcome Leap: Wellcome Leap is a US-based philanthropic program funded by Wellcome Trust that funds breakthrough health research at scale. It shares CTA's model of fast, flexible philanthropic funding for health R&D and is backed by one of CTA's own founding donors.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about COVID-19 Therapeutics Accelerator